Loading
IMpactMF is the first myelofibrosis trial designed to prove that a drug helps people live longer rather than just shrinking the spleen; it compares the telomerase blocker imetelstat with the best treatment doctors can otherwise offer after a JAK inhibitor has stopped working, and results are expected towards 2028.
IMpactMF is Geron's open-label randomised phase 3 trial in patients with intermediate-2 or high-risk myelofibrosis whose disease has relapsed after or is refractory to a JAK inhibitor. Patients are randomised two to one to imetelstat, an oligonucleotide inhibitor of telomerase, or best available therapy excluding JAK inhibitors. Unusually for myelofibrosis, the primary endpoint is overall survival, following the phase 2 IMbark study in which imetelstat was associated with longer survival than expected in this population.
The registry lists 327 participants enrolled with a primary completion date of June 2028 and no results. Imetelstat is approved for lower-risk myelodysplastic syndrome with transfusion-dependent anaemia; the corpus's primary myelofibrosis page cites IMpactMF as the trial testing it after JAK inhibitor failure.
Shares Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Small-molecule kinase inhibitors and the tag soc-trials.
Shares Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Small-molecule kinase inhibitors and the tag soc-trials.
Shares Small-molecule kinase inhibitors and the tag soc-trials.
Shares Small-molecule kinase inhibitors and the tag soc-trials.
Shares Small-molecule kinase inhibitors and the tag soc-trials.
Shares Small-molecule kinase inhibitors and the tag soc-trials.
Shares Small-molecule kinase inhibitors and the tag soc-trials.
Shares Small-molecule kinase inhibitors and the tag soc-trials.